Association between renal function and platelet reactivity during aspirin therapy in elderly patients with atherosclerotic cardiovascular disease [post]

Wenyi Liang, Peng Zhang, Meilin Liu
2020 unpublished
Background: Aspirin is the key treatment in the secondary prevention of atherosclerotic cardiovascular disease. High on-treatment platelet reactivity (HTPR) to aspirin has been reported to partially account for the enhanced risk of thrombotic events. In particular, HTPR has been described more frequently among elderly patients. The aim of this study was to identify the clinical and biological factors associated with HTPR in a real-life elderly population.Methods: In this retrospective study,
more » ... erly patients with atherosclerotic cardiovascular disease on regular aspirin treatment were enrolled. Cardiovascular risk factors, routine biological parameters, comorbidities, and concomitant medications were recorded. The upper quartile of the platelet aggregation rate, determined by light transmission aggregometry with arachidonic acid, was defined as the HTPR group.Results: A total of 304 patients were included (mean age 77 ± 8 years, 76% men). Patients in the HTPR group were older than the patients in the non-HTPR group (mean age: 79 ± 7 vs. 76 ± 8 years, p = 0.008). Patients with moderately decreased estimated glomerular filtration rate (eGFR) had a higher frequency of HTPR than patients with slightly decreased eGFR or normal eGFR (35.8%, 22.5%, 12.2%, respectively, p < 0.05). In multivariate analysis, an independent risk factor for HTPR was the eGFR (OR: 0.984, 95% CI: 0.980-0.988, p < 0.001).Conclusions: Advanced age and decreased eGFR are correlated with poor pharmacodynamic response to aspirin. Antiplatelet strategy in elderly patients with atherosclerotic cardiovascular disease should be driven by an individualized approach, especially in patients with impaired renal function.
doi:10.21203/ fatcat:okyve662tbbkxeiweojj7rir2q